Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VIVUS has been notified by Auxilium Pharmaceuticals, a subsidiary of Endo International, of Auxilium's intention to return the US and Canadian commercial rights for STENDRA (Avanafil) to VIVUS.
Subscribe to our email newsletter
Auxilium has provided its contractually obligated six-month notice of termination which, absent an agreement between Auxilium and VIVUS for an earlier date, will result in the termination of the license and supply agreement on June 30, 2016.
VIVUS CEO Seth Fischer said: "We are excited to reacquire the U.S. and Canadian commercial rights for STENDRA. We appreciate Endo’s efforts to build the STENDRA brand and understand their decision to focus their resources on BELBUCA.
"With STENDRA’s 15 minute onset-of-action, efficacy, ability to be taken with food and alcohol, and safety profile, we remain confident in STENDRA’s long-term prospects.
"We are in the process of evaluating ways for maximizing the value of STENDRA and expect to make an announcement by the end of the first quarter of 2016 with our decision. As part of this process, we are working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS."